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Primary aldosteronism and coronary-pulmonary 
artery fistula: coincidence or causal link?  
A case report and literature review
Luigi Marzano
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Abstract
Background: Primary aldosteronism (PA) is the most frequent form of potentially reversible hypertension and 
coronary-pulmonary fistulas are increasingly recognized during routine coronary angiography or multidetector com-
puted tomography for analysis of chest pain in hypertensive patients. Aldosterone hypersecretion has been associated 
with endothelial proliferation and pathological remodeling of the heart and arteries, though coronary artery fistulas 
have never been reported in patients with PA. 
Case presentation: The authors report the first case of PA with dilated cardiomyopathy unusually associated with 
electrocardiographic changes after normalization of hypokalemia and with the finding of a coronary-pulmonary 
fistula during coronary angiography. The clinical presentation and our diagnosis and treatment decision-making in 
the COVID-19 era are discussed below.
Conclusions: Our case suggests a potential link between hypertensive patients with coronary artery fistulas and PA. 
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Introduction
Although primary aldosteronism (PA) was initially 
considered a rarity, now it is one of the most com-
mon causes of secondary hypertension in which al-
dosterone production is inappropriately high and 
partially autonomous from the renin-angiotensin 
system. Broadly, PA can be dichotomized to unilat-
eral aldosterone production from the left or right ad-
renal gland (aldosterone-producing adenoma; APA, 
or Conn’s syndrome) or bilateral hyperaldosteronism 
(BHA). APA can be cured surgically and it is there-
fore important to distinguish it from BHA, which is 
managed medically with mineralocorticoid receptor 
antagonists. Appropriate diagnostic management of 
PA consists of three consecutive steps: first, screen-
ing test with the aldosterone to renin ratio, then case 
confirmation through the aldosterone suppression 
tests and last, discrimination of unilateral from bilat-
eral forms of PA by adrenal venous sampling. 
Our case highlights an atypical clinical presenta-
tion of PA and our choice of a diagnostic therapeutic 
decision-making plan amid the delicate and complex 
first spread of COVID-19 in Italy.
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Case presentation
A 53-year-old Caucasian obese man with a history of 
modest fatigue and subjective dyspnea was admitted 
to our hospital after undergoing an outpatient trans-
thoracic echocardiography (TTE) that showed car-
diac dysfunction in March 2020, amid the pandemic 
of COVID-19. The patient had been in good health 
until 2 months before the current admission, when 
he saw his primary care physician for the first time 
presenting an asthenia lasting some weeks. Blood 
pressure (BP) taken in office was repeatedly noted to 
be 210/110 mm Hg regardless ongoing therapy with 
three blood-lowering drugs 
Owing to his recent history of fatigue and fre-
quently reoccurring atrial and ventricular extrasys-
toles (the patient was scheduled for 24-hour ECG 
monitoring, TTE and exercise stress test (EST). 
As the TTE documented moderately dilated and 
hypertrophic left ventricle with a decreased contrac-
tility of the inferior and septal walls as well as mod-
estly reduced ejection fraction (Tab. 1) the patient 
after the negative result for SARS-CoV-2 RNA test-
ing was admitted in our department for detailed 
evaluation.
On admission, the patient was obese (BMI = 37 
kg/m2) and had a two-month history of poorly con-
trolled hypertension, treated with amlodipine 10 mg, 
ramipril 5 mg and bisoprolol 1.25 mg a day. His 
father had ischemic cardiomyopathy but there was 
no family history of sudden cardiac death. He did 
not drink alcohol, smoke tobacco or use illegal drugs 
and reported drinking about 2.5 liters of water a day 
and snoring during the night without experienc-
ing daytime sleepiness. On physical examination, 
heart rate was 104 beats per minute and the BP was 
140/110 mm Hg, respiratory rate of 16 breaths per 
minute and the oxygen saturation 97% while the 
patient was breathing ambient air. Laboratory tests 
(Fig. 1) revealed mild to moderate hypokalemia and 
the arterial blood gas showed hypoxemia and pri-
mary metabolic alkalosis with a secondary respiratory 
alkalosis. HbA1c levels were diagnostic for new onset 
type 2 diabetes mellitus. A chest X-ray and ECG per-
formed at the time of admission were unremarkable 
as well (Fig. 2A).
Investigations
During the wide spread of coronavirus, it was neces-
sary to invest few resources in a targeted manner and 
to contain the risk of hospital infections with rapid 
and effective hospitalizations. In such circumstances, 
we studied the renin-angiotensin-aldosterone system 
after only one week of therapy with a calcium chan-
nel blocker and a serum potassium > 4 mmol/L with 
oral potassium supplements.
The aldosterone/renin ratio screening test was 
compatible with a suspected PA, later proved by 
the lack of aldosterone suppression after intrave-
nous saline load (2 L of 0.9% saline infused over 4 
h) (Fig. 1). The subtype diagnosis of PA was made 
by means of abdomen CT scan, which showed an 
adenoma of 7 mm in diameter in the lateral limb of 
the right adrenal gland and a slight thickening of the 
contralateral gland (Fig. 3A).
It was surprising to notice that, 18 hours after hos-
pitalization and oral potassium supplementation, in 
the absence of symptoms or secondary causes, sig-
nificant changes were observed in the ventricular re-
polarization on ECG (Fig. 2B) with indications by the 
cardiologist to perform a coronary angiography and 
start dual antiplatelet therapy with aspirin and clopi-
dogrel. Selective coronary angiography showed a right 
dominant coronary circulation and a slightly reduced 
left ventricular function due to diffuse hypokinesia, 
without evidence of significant stenoses. Furthermore, 
the presence of a fistula from the left anterior descend-
ing coronary draining into the pulmonary branch 
was detected (Fig. 3B). After a week from admission, 
we observed a progressive and complete normaliza-
tion of ventricular repolarization on the ECG and 
a twenty-four hour Holter monitoring showed a sinus 
rhythm with no significant arrhythmias.
Table 1. Change in echocardiogram parameters before and after 9 weeks of medical treatment†
Before treatment March 9, 2020 After treatment May 15, 2020 Reference range, Adults
LVEDVI [mL/m²] 95 67 < 75
LVEF (%) 43 51 ≥ 52
LAVI [mL/m²] 39 25 ≤ 34
PWT [mm] 12 10 < 11
IVS [mm] 13 12 < 11
†Spironolactone 100 mg, amlodipine 5 mg and bisoprolol 2.5 mg daily. LVEDVI indicates LV end-diastolic volume index; LVEF — LV ejection fraction; LAVI — LA volume index;  
PWT — posterior wall thickness; IVS — interventricular septal thickness
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Treatment
Current guidelines suggest the use of unilateral adre-
nalectomy or mineralocorticoid receptor antagonists 
(MRA) for the treatment of PA with or without lat-
eralized aldosterone secretion, respectively [1].
Due to the complex and delicate COVID-19 
pandemic and in compliance with the WHO dec-
laration and the United States Surgeon General’s 
recommendations [2] suggesting to cancel elective 
surgeries at hospitals with the concern that elec-
tive procedures within facilities may contribute to 
the spreading of the coronavirus so as to utilize 
the medical resources needed to manage a potential 
increase of coronavirus cases, we discharged the pa-
tient with a MRA therapy, waiting to perform the 
adrenal venous sampling in order to confirm the 
lateralization of overproduction of aldosterone for 
the best treatment.
Figure 1. Timeline. ER — emergency room; US — ultrasound; CT — computed tomography; PA — primary aldosteronism; CMP — cardio-
myopathy; CPF — coronary-pulmonary artery fistula; SBP/DBP — systolic and diastolic blood pressure; TSH — thyroid-stimulating hormone; 
NT pro-BNP — N-terminal pro-B-type natriuretic peptide; ABG — arterial blood gas; ODST — overnight dexamethasone suppression test; 
SLST — saline load suppression test performed with calcium channel blocker and serum potassium 4 mmol/liter. To convert the values for 
glucose to millimoles per liter, multiply by 0.05551. To convert the values for creatinine to micromoles per liter, multiply by 88.4. †Reference 
values are affected by many variables, including the patient population and the laboratory methods used. The ranges used at our Hospital are 
for adults who are not pregnant and do not have medical conditions that could affect the results. They may therefore not be appropriate for all 
patients
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Outcome and follow-up
About two weeks after discharge, we achieved the 
normalization of plasma potassium levels and a suf-
ficient BP control with spironolactone 100 mg, amlo-
dipine 5 mg and bisoprolol 2.5 mg a day. Currently in 
medical treatment the patient is still under follow-up 
in our clinic with good clinical and echocardiographic 
outcomes [3, 4] (Tab. 1) and no complications.
Discussion
Hypertensive patients with PA showed the in-
creased risk of coronary artery disease, heart failure, 
atrial fibrillation and stroke, compared with patients 
with essential hypertension [5]. The classic present-
ing signs of PA are resistant or difficult-to-control 
hypertension and hypokalemia, but less than half 
of the cases show these two conditions [1] and also 
because of this the unsuppressible (primary) hyper-
secretion of aldosterone is often an underdiagnosed 
cause of hypertension.
A wide body of experimental and clinical research-
es has demonstrated that inappropriately increased 
aldosterone secretion induces a significant inflam-
mation, remodeling and fibrosis on cardiovascular 
system, including endothelial proliferation and vas-
cular remodeling, which cannot be explained only 
by the increased degree of blood pressure [6–10]. Yet 
a link between primary aldosterone hypersecretion 
and coronary artery fistulas has never been reported.
In 1964, James O. Davis et al. have investigated 
on animal models the aldosterone secretion and the 
mechanisms which lead to hypersecretion of aldo-
sterone in experimental high-output heart failure 
secondary to an aortic-caval fistula [11]. Higher 
aldosterone concentrations in patients free from 
overt cardiovascular disease are associated with the 
increased risk of subclinical coronary atherosclero-
sis and all-cause mortality particularly among indi-
viduals with renin suppression [12]. In patients with 
PA, complex mechanisms may lead to functional and 
structural abnormalities of the blood vessels walls. 
Clinical evidence indicates that PA patients may have 
immune cell activation, increased oxidative stress, 
Figure 2. Twelve-lead ECG tracing done upon the arrival of the 
patient at the emergency room (A). ECG tracing showing negative 
T wave in the precordial leads V2-6 after 18 hours from admission 
and oral supplement of slow-release potassium chloride (600 mg or 




Figure 3. Transverse CT scan of the abdomen showing a nodule in the lateral limb of the right adrenal gland (Arrow) compatible with 
the adenoma measuring 7 mm (A). Coronary angiogram clearly showing a coronary artery fistula (Arrow) between the proximal left anterior 
descending artery and the pulmonary artery (B)
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dial effusion, coronary arterial steal phenomenon, 
thrombosis and myocardial infarction [19]. The 
American Heart Association/American College of 
Cardiology guidelines suggest the transcatheter oc-
clusion for symptomatic fistulas and for moder-
ate or large fistulas without clinical manifestations 
[18]. Nevertheless, the best approach to the asymp-
tomatic CPFs is still controversial.
The excellent echocardiographic results observed 
after 2 months of MRA therapy support the hypoth-
esis that PA was the primary cause of dilated car-
diomyopathy in our patient and his mild-moderate 
CPF currently deserves a careful follow-up for the 
appearance of symptoms.
Both PA and CPFs might be associated with ECG 
changes and arrhythmias. However, a paradoxical 
T-wave inversion in the precordial leads was observed 
in our patient after oral potassium supplementation. 
Changes in electrolyte levels can affect depolarization 
and/or repolarization and can cause ECG changes. 
In a recent prospective study on hospitalized hy-
pokalemic patients, it was found that 85% of them 
experienced ECG changes after potassium correc-
tion and 36% of patients who showed a T-flat or 
T-inverted might have a T-wave inversion after potas-
sium supplementation. In addition to this, there was 
no significant relationship between post-correction 
potassium levels and ECG changes [20].
Conclusions
In summary, the presented case highlights novel as-
pects related to PA and its diagnostic algorithms. 
Therefore, we strongly recommend cardiologists and 
clinicians to maintain a high level of suspicion of PA 
in hypertensive patients with finding of coronary 
artery fistulas (Tab. 2). Further studies will be needed 
to clarify this association.
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endothelial dysfunction and proliferation with vascu-
lar remodeling [13]. There is evidence that aldosterone 
via the mineralocorticoid receptor (MR) promotes 
angiogenesis. In vitro findings, aldosterone exacerbat-
ed retinal neovascularization in ischemic retinopathy 
which was attenuated with MR antagonist (MRA). 
The aldosterone infusion increased VEGF mRNA 
levels and neovascularization in mice with hindlimb 
ischemia, and these events were reduced with spi-
ronolactone [14]. It was also noticed that in a mouse 
model, a modest increase in plasma aldosterone con-
centration can modulate cardiac genes expression and 
induce the proliferation of cardiac endothelial cells 
in vivo. Aldosterone‐induced MR-dependent prolif-
eration was confirmed ex vivo in human endothelial 
cells and the pharmacological‐specific blockade of 
the MR by eplerenone inhibited endothelial prolif-
eration in a rat model of heart failure [7]. Recently, 
Rho-associated kinase (ROCK) activity has drawn 
attention for its crucial role in angiogenesis [15] and 
the treatment with eplerenone for 12 weeks improves 
arterial stiffness, vascular smooth muscle function 
and microvascular endothelial function, and inhibits 
ROCK activity in patients with PA [16].
Thus far, however, PA has not been reported as 
a clear cause for dilated cardiomyopathy [17] or 
coronary arteriovenous fistulas.
Coronary-pulmonary fistulas (CPFs) are rare 
congenital or acquired coronary artery anoma-
lies that can originate from any of the three ma-
jor coronary arteries and drain into any of the 
cardiac chambers and great vessels. According to 
a literature review, the published epidemiologi-
cal data may underestimate the real prevalence of 
the coronary artery fistulas in the general popula-
tion, while the incidence in the echocardiographic 
series was 0.06 to 0.2%, in the necropsy series 
14%, and in the angiographic series was 0.1% to 
0.67% [18]. Furthermore, with the increasing use 
of the coronary artery angiography and multide-
tector computed tomography for the analysis of 
chest pain, the number of incidentally detected 
unilateral and multilateral CPFs has been gradu-
ally rising [18]. Although they are often incidental 
findings, patients with CPFs may have arrhyth-
mias, angina, dyspnea, congestive heart failure, 
pulmonary hypertension, endocarditis, and sud-
den cardiac death. Therefore, their potential clini-
cal consequences require further investigation in 
order to adopt either interventional (percutaneous 
transcatheter closure/surgical ligation) or conserva-
tive treatment, preventing any complications such 
as aneurysm creation, vessel dissection, pericar-
arterial hypertension 2021, vol. 25, no. 1
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Table 2. Learning points and take-home messages
• Hypertensive crises in the emergency room are often underestimated. Patients, particularly if young and presenting spontaneous hypokalemia, 
should be referred initially to the Hypertension Reference Centers for screening and/or early diagnosis of secondary forms of hypertension.
• The finding of CPFs in hypertensive patients should lead to a high suspicion of underlying PA.
• In patients with PA and chronic hypokalemia, the correction of serum potassium levels might be associated with transient T-wave inversion  
on the ECG.
• PA should be excluded as a potential cause of dilated cardiomyopathy, because evidence suggests that there may be a probable causal  
relationship between dilated cardiomyopathy and PA [17]. 
• The clinical practice guidelines for case detection, diagnosis, and treatment of PA are an essential part of quality medical practice, though  
the flexibility in diagnostic and therapeutic decision-making is sometimes the only alternative available, such as during the CoViD-19  
pandemic crisis.
CPFs — coronary-pulmonary fistulas; PA — primary aldosteronism
